# Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

> **NCT00918047** · PHASE1 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

- **DRUG:** SPN-804O

## Key facts

- **NCT ID:** NCT00918047
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918047, "Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00918047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*